Alpine Immune Sciences Performance
| ALPNDelisted Stock | USD 12.37 0.23 1.83% |
The firm shows a Beta (market volatility) of 0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Alpine Immune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Alpine Immune is expected to be smaller as well. Alpine Immune Sciences right now shows a risk of 0.0%. Please confirm Alpine Immune Sciences semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Alpine Immune Sciences will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Alpine Immune Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Alpine Immune is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 13.4 M |
Alpine |
Alpine Immune Relative Risk vs. Return Landscape
If you would invest (100.00) in Alpine Immune Sciences on August 29, 2024 and sell it today you would earn a total of 100.00 from holding Alpine Immune Sciences or generate -100.0% return on investment over 90 days. Alpine Immune Sciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Alpine, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alpine Immune Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alpine Immune's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alpine Immune Sciences, and traders can use it to determine the average amount a Alpine Immune's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ALPN |
Based on monthly moving average Alpine Immune is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alpine Immune by adding Alpine Immune to a well-diversified portfolio.
Alpine Immune Fundamentals Growth
Alpine Stock prices reflect investors' perceptions of the future prospects and financial health of Alpine Immune, and Alpine Immune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alpine Stock performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (0.65) % | |||
| Operating Margin | (3.23) % | |||
| Current Valuation | 4.16 B | |||
| Shares Outstanding | 68.6 M | |||
| Price To Earning | (32.69) X | |||
| Price To Book | 12.87 X | |||
| Price To Sales | 71.68 X | |||
| Revenue | 58.88 M | |||
| EBITDA | (43.67 M) | |||
| Cash And Equivalents | 167.86 M | |||
| Cash Per Share | 5.52 X | |||
| Total Debt | 9.91 M | |||
| Debt To Equity | 0.17 % | |||
| Book Value Per Share | 5.08 X | |||
| Cash Flow From Operations | (79.01 M) | |||
| Earnings Per Share | (0.64) X | |||
| Total Asset | 381.81 M | |||
| Retained Earnings | (256.14 M) | |||
| Current Asset | 25.53 M | |||
| Current Liabilities | 3.39 M | |||
About Alpine Immune Performance
By examining Alpine Immune's fundamental ratios, stakeholders can obtain critical insights into Alpine Immune's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Alpine Immune is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Alpine Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people.Things to note about Alpine Immune Sciences performance evaluation
Checking the ongoing alerts about Alpine Immune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alpine Immune Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alpine Immune is not yet fully synchronised with the market data | |
| Alpine Immune has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 58.88 M. Net Loss for the year was (32.18 M) with loss before overhead, payroll, taxes, and interest of (40.18 M). | |
| Alpine Immune Sciences currently holds about 167.86 M in cash with (79.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.52. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Alpine Immune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alpine Immune's stock is overvalued or undervalued compared to its peers.
- Examining Alpine Immune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alpine Immune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alpine Immune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alpine Immune's stock. These opinions can provide insight into Alpine Immune's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |